iTheranostics, Novartis ink FAP-targeted drug development agreement

By The Science Advisory Board staff writers

Sofie subsidiary iTheranostics has inked an agreement with Novartis to collaborate on the development of therapeutic fibroblast activation protein (FAP)-targeted agents.

iTheranostics' library of these drugs has been licensed from the University of Heidelberg in Germany. Under the terms of the deal, Novartis will develop therapeutic uses of this family of compounds, while iTheranostics will be responsible for commercializing the developed imaging agents.

Sofie may facilitate clinical supply and will be responsible for the commercialization of FAP-targeted positron emission tomography (PET) imaging tracers around the world, it said.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?